Previous close | 0.9500 |
Open | 0.9658 |
Bid | 0.9116 x 500 |
Ask | 0.9462 x 400 |
Day's range | 0.9000 - 0.9942 |
52-week range | 0.6100 - 9.3720 |
Volume | |
Avg. volume | 1,159,501 |
Market cap | 19.914M |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.
On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024. VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options. Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule: The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT)
Comparing Vincerx Pharma's Performance Against Analyst Estimates